Ann: AML patient achieves Complete Response in CHM CORE-NK trial, page-56

It is similar to any other allogeneic CAR-Ts, just different targetsArovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.

NK is allogeneic as well.

Now, tell me how the difference in valuation, considering CHMs other assets as well, is justified. Let's compare the pre-clinical first, to have a leveled playing field. CHM had no problems to get their cell production sorted and got the IND plus first patient dosed for its CDH17 CAR-T within 3 years. How is ALA doing in that regards with its ALA-101?

Again, if ALA-101 is already hailed as the ultimate cancer cure why has IMU terminated the colab and why hasn't ALA being able to get the IND requirements done yet?

In the end, it is the big gap in valuation that I can't understand and if ALA can despite the above problems, why can't CHM?


GLTA